Member Info for quercusrobor

ok...and what do you suggest is the scenario that have to look forward to?

Significant Shareholders | 2 April 2021
Significant Shareholders Number of Shares % of Issued Ordinary Share Capital
Amati AIM VCT plc 51,136,000 8.19%
Hargreaves Lansdown (Nominees) Limited 33,293,719 5.33%
Mr Alastair Ferguson 29,494,242 4.72%
Intertrust Employee Benefit Trustee Limited as trustee of The Block Energy plc Employee Benefit Trust 28,681,092 4.59%
G.P. (Jersey) Limited 26,750,000 4.29%
Hargreaves Lansdown (Nominees) Limited 25,720,551 4.12%
Global Prime Partners (Jon Fitzpatrick) 24,516,264 3.93%
JIM Nominees Limited 23,101,816 3.70%
Hargreaves Lansdown (Nominees) Limited 21,494,927 3.44%
Vidacos Nominees Limited 21,490,019 3.44%
Interactive Investor Services Nominees Limited 21,129,456 3.38%
Mr Paul Haywood (Director) 12,544,381 2.01%
Plutus Strategies Ltd (of which Paul Haywood is a shareholder) 3,166,837 0.51%
Mr Philip Anthony Dimmock (Director) 1,367,983 0.22%
Mr William McAvock (Director) 653,517 0.11%
Mr Chris Brown (Director) 568,347 0.09%
https://www.blockenergy.co.uk/investors/significant-shareholders/

re...Perhaps the Concert Party buying..
who are the concert party+what is their assumed agenda?

re...This is my first experience of this. Is there a benefit to doing so as seems like a lot of hassle.

seems to me that there is a lot of unnecessary 'confusion' being sown here....in my limited experience it makes not a jot of difference..the London/US prices will always be more or less in alignment.All this chatter about arbitrage is for the birds...(imho)...unless of course your trading skills and timing are sublime.There are plenty of examples of London listed PLC's also listed on US exchanges...Arb,Ika, to name but two.
My advice ...from the backwoods;0....relax and enjoy the ride.

https://www.dailymail.co.uk/home/index.html

FAPa-Activated Doxorubicin Prodrug

AVA6000 is Avacta’s first-in-class FAPa-activated prodrug based on the pre|CISION™ platform, providing a prodrug form of doxorubicin with an improved safety profile enabling broader use in oncology, particularly in combinations with immuno-oncology drug agents, according to company officials. Avacta has submitted a Clinical Trial Application (CTA) in the United Kingdom for a Phase I, first-in-human, open-label, dose-escalation and expansion study of AVA6000, in patients with locally advanced or metastatic selected solid tumors.

In its prodrug form, the doxorubicin drug moiety is inactive in the circulation until it enters the solid tumor microenvironment, where it is activated by the enzyme FAPa (fibroblast-activating protein alpha), which is in high abundance in most solid tumors but not in healthy tissue such as heart tissue. In the solid tumor microenvironment, the FAPa substrate is cleaved and the active doxorubicin drug is released, causing a significant differential targeting of tumor tissue compared with healthy tissue.

“A prodrug doxorubicin with a significantly improved safety profile should result in an expanded eligible patient population in the indications to which doxorubicin is currently limited because of cardiotoxicity issues and longer dosing regimens, and provide for a much more widespread utility across the field of oncology,” explains Neil Bell, chief development officer for Avacta. “In addition, if the AVA6000 study shows that the pre|CISION chemistry is effective in reducing systemic toxicity of doxorubicin in humans, then it can be applied to a range of other established chemotherapies to improve their safety and efficacy.”

re.... What is this place, a Russian state controlled oligarchy./autocracy....

getting closer every day...

re... You may get attacked by someone with a slotted liner or swellable packer.

oooooh...you are awful!......
swellable packer sounds ideal remedy for some people on here;0

re..Becuase there is concerted dump taking place chip at a time becuase of EWT till 28th April and Block waiting to confirm recipt of revenue from Bago/GOGC. As the Block concert party at this stage are expressing no confidence that they will even pay up never mind flow rates. That is untill they are able to buy the company for peanuts.

What exactly are you suggesting?

re.... As the Block concert party at this stage are expressing no confidence that they will even pay up never mind flow rates. That is untill they are able to buy the company for peanuts.

which in language for the peasants..(moi)..that means?

presumably if Joe is earning say £3000/month...and is being paid in Bloe shares it is hugely to his advantage for the sp to be as low as possible...or am I missing something?.

sp now back to where it was in MARCH 2020....all seems to be considerably less than straighforward here....or am I just very naive?

https://www.powerof78.com/2021/03/28/eua-mar2021/

Posted on 28 March 2021 by gmf78
#EUA – Valuations update 28.3.21

from Alex Anstruther

Incase anybody needs reassurance, and it seems a lot of you might for some reason, today was the first day EVER that 4D traded above it’s 200WMA. Ok so it didn’t close above, that’s ok. It is a big deal, we will try again over the coming days or weeks and once we clear that hurdle the sky truly is the limit.

.... he's making mischief then that's his call but it doesn't do much for reputation.
..... He is suggesting there is some real tension among major shareholders but at the same time highlighting PHs buys as a sign of good things to come?
.... but the thought that current employees would jump in bed with 3rd party share holders is staggering.

cldnt agree more with those points...
a great example of very sloppy journalism designed to stir the pot and create mischief.....no facts...all conjecture...and clearly 3rd party input....get a life Malcy,.....oh and by the way....how about some sunbstantive facts...or are you suffering from extreme cabin fever and an over active imagination.

Block Shareholder Action Group..????
has anyone heard of such a group?....is membership by invitation only...or is this typical cheapo hack pot stirring?

Block Energy

I noticed yesterday that yet another RNS from Block Energy confirming the exercise of options and PDMR dealing. This time CEO Paul Haywood has exercised his options to acquire 4,400,000 shares at 2.5p per share. This is part of a pattern of activity by board members over recent weeks to exercise options and making share awards.

My reading of this is that there is growing expectation around the production testing programme which is planned to monitor reservoir production and facility parameters in order to determine the maximum flow potential and optimum production rates. The company will continue the testing programme into Q2 this year and, on completion establish stable production from the West Rustavi wells.

Additionally I am hearing that there is some dissatisfaction amongst the ranks of existing and former employees, contractors and consultants who were forced to take 40% + of their salaries in BLOE equity back in April 2020. The plan to cut costs may have unwittingly played into the hands of the dissenting major shareholders as with many of these unhappy campers now outside the tent they appear to be adding further weight to the Block Shareholder Action Group which is pondering its next move.

This has played out for some time now but with these option moves rather telegraphing strategy they may have encouraged the dissidents to play ‘Check’ one more time and ‘Check Mate’ may only be a move or two away one might surmise. This is one to watch in the continued cat and mouse game that shareholders are playing…

and what exactly is all this about?

https://www.malcysblog.com/2021/03/oil-price-genel-iog-bpc-predator-block-and-finally/

https://www.thetimes.co.uk/article/covid-19-testing-will-become-permanent-feature-of-life-documents-reveal-kcl5p3vsd

for the record...https://www.businesswire.com/news/home/20210208005301/en/Avacta-and-Mologic-Announce-Commercial-Partnership

re.Has anyone seen the news that Mologic have jumped ship to assist Aptamer? ...laughable...no-one has 'jumped ship' as you put it....try harder...or you will be even more'concerned' than you are already;)

Going into 2022 sales could pick up slightly to $650m, with a break back upwards into profitability of around $5m.

Undervalued assets

On the face of it, that looks both dismal and dull, but I have faith in the group’s management to safely turn the group’s profitability around before resuming its previous growth path.

The group had net assets of $976m, at the last balance sheet date, with $101.7m cash in the bank.

With some 165m shares in issue the group is today capitalised at only £454m ($630m).

It is obvious that the group has a strong enough balance sheet and cashflow to cope with its recovery back into profitability this year. About £702m of assets shows the company standing at around a 35% discount.

Broker ratings

Brokers are not in unison as to their price objectives for the group’s shares – RBS rate the shares a ‘sector perform’ up to 305p, while Jefferies rate the shares as a ‘buy’ looking for 360p. Barclays raised its price from 260p to 300p and recommend ‘overweight’ portfolio positions.

Less than three years ago the shares were trading at 845p, but by September of last year they had eased back to just 120p. At the start of this month the shares peaked at 297p, and they closed at 275p last Friday night.

My view

I am looking for the shares to be back over that peak and heading for 350p fairly soon and then head even higher.

Accordingly, I now set my target price at 350p.